Description

BSE lists 1,06,668 new equity shares of Fredun Pharmaceuticals Limited issued to promoters on preferential basis via warrant conversion, effective May 4, 2026.

Summary

BSE has listed 1,06,668 new equity shares of Fredun Pharmaceuticals Limited (Scrip Code: 539730) effective Monday, May 4, 2026. These shares were issued to promoters on a preferential basis pursuant to conversion of warrants at an issue price of Rs. 1,250 per share (face value Rs. 10 + premium Rs. 1,240). The new shares rank pari-passu with existing equity shares of the company.

Key Points

  • 1,06,668 equity shares of Rs. 10/- each issued at a premium of Rs. 1,240/- (issue price Rs. 1,250/-)
  • Issued to Promoters on a preferential basis via conversion of warrants
  • Shares rank pari-passu with existing equity shares
  • Distribution numbers: 5410323 to 5516990
  • ISIN: INE194R01017
  • All 1,06,668 newly issued shares are subject to lock-in until 30/11/2027

Regulatory Changes

No new regulatory changes. This is a standard listing notice following preferential allotment under SEBI’s preferential issue regulations.

Compliance Requirements

Trading members of BSE are informed that these securities are now listed and permitted to trade from May 4, 2026, subject to the lock-in restrictions applicable to the promoter allotment.

Important Dates

  • Date of Allotment: 25 March 2026
  • Effective Trading Date: Monday, 4 May 2026
  • Lock-in Expiry: 30 November 2027

Impact Assessment

The listing adds 1,06,668 shares to the tradeable universe of Fredun Pharmaceuticals Limited (539730), though the full allotment is locked in until November 2027, meaning no additional free-float is created in the near term. The preferential allotment to promoters at Rs. 1,250 per share signals promoter confidence at that valuation level. Market impact is expected to be minimal given the lock-in restriction.

Impact Justification

Routine listing of new equity shares via preferential allotment to promoters following warrant conversion; relatively small share count with lock-in until November 2027, limiting near-term trading impact.